International Consensus on Diverticulosis and Diverticular Disease.

Statements from the 3rd International Symposium on Diverticular Disease

Antonio Tursi1, Giovanni Brandimarte2, Francesco Di Mario3, Angel Lana4, Carmelo Scarpiognato5, Mauro Bafutto6, Giovanni Barbara7, Gabrio Bassotti8, Gian Andrea Binda9, Alberto Biondi10, Sebastiano Biondi11, Ginevra Cambie12, Claudio Cassieri12, Antonio Crucitti12, Dan L. Dumitrascu13, Walter Elisei14, Riccardo Escalante15, Łaszłó Herszenyi16, Wolfgang Kruis17, Juozas Kupcinskas18, Adi Lahat19, Piera G. Lecca20, Giovanni Magoni21, Peter Malferttheiner22, Andrea Mazzari23, Tomica Milosavljevic23, Gerardo Nardone24, Enio Chavez de Oliveira25, Alfredo Papa26, Savvas Papagrigoriadis27, Miguel Pera28, Roberto Persiani29, Marcello Picchio29, Jaroslaw Regula30, Davor Štimac31, Neil Stollman32, Lisa L. Strate33, Alessandra Violi3, Marjorie M.D. Walker4

1) Gastroenterology Service, ASL BAT, Andria (BT), Italy; 2) Division of Internal Medicine and Gastroenterology, “Cristo Re” Hospital, Rome, Italy; 3) Department of Medicine and Surgery, Gastroenterology Unit, University of Parma, Parma, Italy; 4) Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, Zaragoza, Spain; 5) Faculty of Medical Sciences, United Campus of Malta, San Giljan, Malta; 6) Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda, Rua 246, 25 Setor Coimbra, Goiânia, Goiás, Brazil; 7) Department of Clinical Medicine, Section of Gastroenterology, “S. Orsola” Hospital, University of Bologna, Bologna, Italy; 8) Department of Clinical and Experimental Medicine, Gastroenterology and Hepatology Section, “Santa Maria della Misericordia” Hospital, University of Perugia, San Sisto (PG), Italy; 9) Department of Surgery, “Galliera” Hospital, Genoa, Italy; 10) Department of Surgical Sciences, First General Surgery Unit, Catholic University, “A. Gemelli” University Hospital, Rome, Italy; 11) Department of General and Digestive Surgery, Colorectal Unit, Bellvitge University Hospital and IDIBELL, University of Barcelona, Barcelona, Spain; 12) Division of General Surgery, “Cristo Re” Hospital, Rome, Italy; 13) 2nd Medical Department, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania; 14) Division of Gastroenterology, ASL Roma 6, Albano Laziale (Roma), Italy; 15) Universidad Central de Venezuela, Loira Medical Center, Caracas, Venezuela; 16) 2nd Department of Medicine, Semmelweis University, H-1088 Budapest, Hungary; 17) Innere Medizin, Evangelische Krankenhaus Kalk, Cologne, Germany; 18) Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas; Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 19) Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 52651, Israel; 20) Gastrointestinal Unit, Department of Clinical Sciences, “L.Sacco” University Hospital, Milan, Italy; 21) Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany; 22) Servicio Aparato Digestivo, Centro Médico Teknon, Barcelona, Spain; 23) Clinical Centre of Serbia, University of Belgrade, Serbia; 24) Department of Clinical and Experimental Medicine, University „Federico II“, Naples, Italy; 25) Hospital Ortopédico de Goiânia (St Aportoero), Goiânia, Goiás, Brazil; 26) Division of Internal Medicine and Gastroenterology, CIC “Columbus”, Catholic University, “A. Gemelli” University Hospital, Rome, Italy; 27) Department of Colorectal Surgery, King’s College Hospital, London, United Kingdom; 28) Sección de Cirugía Gastrointestinal, Hospital Universitari del Mar, Barcelona, Spain; 29) Division of General Surgery, “P. Colombo” Hospital, ASL Roma 6, Velletri (Roma), Italy; 30) Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Postgraduate Education Centre; Department of Gastrointestinal Oncology, Maria Skłodowska-Curie Clinical Oncology Institute, Warsaw, Poland; 31) Division of Internal Medicine, University Hospital, Rijeka, Croatia; 32) Division of Gastroenterology, Department of Medicine, University of California San Francisco, Oakland, CA, USA; 33) Division of Gastroenterology, Department of Medicine, Harborview Medical Center, University of Washington Medical School, Seattle, Washington, USA; 34) University of Newcastle, Faculty of Health and Medicine, School of Medicine & Public Health, Australian Gastrointestinal Research Alliance, Callaghan NSW 2308, Australia

ABSTRACT

The statements produced by the Chairmen and Speakers of the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11th-13th 2019, are reported. Topics such as current and evolving concepts on the pathogenesis, the course of the disease, the news in diagnosing, hot topics in medical and surgical treatments, and finally, critical issues on the disease were reviewed by the Chairmen who proposed 39 statements graded according to level of evidence and strength of recommendation. Each topic was explored focusing on the more relevant clinical questions. The vote was conducted on a 6-point scale and consensus was defined a priori as 67% agreement of the participants. The voting group consisted of 124 physicians from 18 countries, and agreement with all statements was provided. Comments were added explaining some controversial areas.
INTRODUCTION

Diverticulosis of the colon is the most frequent anatomical alteration of the colon in the developed countries, and the highest rates occur in the United States and Europe. This condition nowadays ranks as the fifth most important gastrointestinal disease in terms of direct and indirect costs [1, 2]. When diverticulosis becomes symptomatic, it is called “diverticular disease” (DD), a term generally including symptomatic uncomplicated diverticular disease (SUDD) and acute diverticulitis (AD) [1, 2].

Although the pathogenesis and management of diverticulosis and DD remain uncertain, new hypotheses and observations are changing the pharmacological and surgical management of DD.

Recommendations for the diagnosis and treatment of DD have been issued by many medical societies in various countries. However, these recommendations are often conflicting [3, 4], generating uncertainties in the clinician and dissatisfaction in patients.

We have summarised the current perspective on DD in this consensus conference report, aiming to develop guidelines for the clinical, diagnostic and therapeutic management of DD in light of the presentations during the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11th-13th, 2019.

METHODS

The primary aim of this document was to provide clinical guidelines for appropriate definition, diagnosis and management of diverticulosis and DD according to the opinion of the participants to the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11-13, 2019. The promoters of this initiative were the Chairmen of this International Symposium (A.T., F.D.M., G.B., A.L., C.S.). This International Symposium on Diverticular Disease was constituted by six main sessions (current and evolving concepts on the pathogenesis, news on the course of the disease, the news in diagnosing, hot topics in medical therapy, hot topics in surgical treatments, and finally critical issues on the disease). The evidence-based Delphi-like process developed consensus statements following proposals by designated speakers. The process allowed individual feedback and changes of views during the process regulated by the coordinators of each session and the Chairmen of the Symposium.

The principal steps in the process were: (a) selection of the consensus group; (b) identification of areas of clinical importance; (c) systematic literature reviews by using Medline/PubMed and the Cochrane Database to identify evidence to support each statement, draft statements and discussion with the coordinators of each session and the Chairmen of the Symposium supported by the evidence specific to each statement. The modified statements of the 2nd International Symposium [5] were used to define statements of this Symposium. Evidence-based discussions with key references were provided for each statement, and a two-rounds assessing statements was conducted.

Each recommendation was graded according to the Oxford Centre for Evidence-Based Medicine, according to the level of evidence (EL) and grade of recommendation (RG) [6]. Participants, constituted by multi-disciplinary professionals/experts such as gastroenterologists, gastrointestinal endoscopists, surgeons, pathologists, internists, infectious diseases and general practitioners, were asked to vote each statement linked to the session at the end of the same session. Chairmen, speakers, and members of the scientific board did not take part to vote statements. The agreement/disagreement level was scored on a six-point Likert scale as follows: A+: strongly agree; A: agree with minor reservations; A-: agree with major reservations; D-: disagree with major reservations; D: disagree with minor reservations; D+: strongly disagree.

Level of agreement was expressed as percentage of each point of the scale. Consensus was defined a priori as agreement by at least 67% of respondents.

The format of the following recommendations comprises the question, the statement, its level of evidence and strength of recommendation, and the percentage agreement of the global consensus group on the final version.

In the present document the statements are accompanied by comments made by Chairmen of the Meeting. In some areas the evidence level is low, reflecting the lack of randomised trials and/or good quality studies. For some topics only the expert opinion was considered, where appropriate.

Analysis was performed only assessing participant voting all statements.

STATEMENTS

One hundred and twenty-four participants voted all statements. They came from 18 countries: 1 from Australia, 5 from Bulgaria, 1 from Croatia, 1 from Germany, 1 from Israel, 60 from Italy, 3 from Mexico, 1 from The Netherlands, 2 from Poland, 2 from Portugal, 2 from Romania, 3 from Russia, 1 from Serbia, 2 from Slovakia, 1 from Slovenia, 3 from Spain, 3 from Tunisia, 1
from Hungary, and 2 from United States of America. One hundred
and two were gastroenterologists, 15 surgeons, 3 internists, 3
general practitioners, and 1 specialist on infectious diseases.

1. Pathogenesis

1.1 There is no sufficient evidence that fiber intake prevents
the development of diverticulosis. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 38.71%; A 41.94%; A-
11.29%; D- 3.23%; D 2.42%; D+ 2.42%.

1.2 Diverticulosis and diverticulitis are more likely
to develop in individuals with genetic predisposition. [EL:
1b; GR: A]
Consensus levels of agreement: A+ 41.13%; A 37.10%; A-
16.94%; D- 1.61%; D 3.23%; D+ 0%.

1.3 The routine clinical use of genetic markers is not
recommended for the prevention, diagnosis and management
of diverticular diseases. [EL: 1b; GR: A]
Consensus levels of agreement: A+ 70.16%; A 13.71%; A-
14.52%; D- 0%; D 0.81%; D+ 0.81%.

1.4 Neuromuscular dysfunction represents a relevant
pathogenetic factor in colonic diverticulosis. [EL: 3a; GR: C]
Consensus levels of agreement: A+ 49.19%; A 38.71%; A-
10.48%; D- 1.61%; D 0%; D+ 0%.

1.5 Colonic motor and sensory abnormalities may play
a role in the genesis of abdominal pain in patients with
colonoscopy symptomatic uncomplicated diverticular disease
(SUDD). [EL: 4a; GR: C]
Consensus levels of agreement: A+ 39.52%; A 46.77%; A-
11.29%; D- 1.61%; D 0%; D+ 0.81%.

1.6 In community subjects and patients attending
colonoscopy with no prior history of diverticulitis and with
asymptomatic diverticulosis and no endoscopic inflammation
it is highly unlikely there will be inflammatory changes in
biopsy of the intervening colonic mucosa. [EL: 1b; GR: A]
Consensus levels of agreement: A+ 56.45%; A 21.77%; A-
12.90%; D- 4.03%; D 4.03%; D+ 0.81%.

1.7 Patients with symptomatic uncomplicated diverticular
disease (SUDD) may have low-grade inflammatory changes
at the molecular level and microbiome in the biopsy without
endoscopic inflammation. [EL 3a; GR: B]
Consensus levels of agreement: A+ 39.52%; A 45.16%; A-
14.52%; D- 0.81%; D 0%; D+ 0%.

1.8 A diet high in dietary fiber is associated with a
decreased risk of diverticulitis. [EL: 2b; GR: D]
Consensus levels of agreement: A+ 52.42%; A 40.32%; A-
2.42%; D- 3.23%; D 0%; D+ 1.61%.

1.9 Obesity is associated with an increased risk of
diverticulitis and diverticular bleeding. [EL: 2a; GR: D]
Consensus levels of agreement: A+ 67.74%; A 24.19%; A-
3.23%; D- 2.42%; D 1.61%; D+ 0.81%.

Comments
These statements point out the new evidences on the
pathogenesis of diverticulosis and diverticular disease. The
first three statement point out the role of genetic factors to
the development of DD and AD [7-14]. The fourth and fifth
statements point out the significant role of neuromuscular
abnormalities in the pathogenesis of diverticulosis and DD
[15-20]. The sixth and the seventh statement point out that
diverticulosis is a merely expression of an anatomical altera-
tion [21-23], while symptomatic uncomplicated diverticular
disease (SUDD) may have overt inflammation microscopic
inflammation even without any endoscopic inflammation [24,
25]. The last two statements point out the role of high fiber diet
in reducing the risk of acute diverticulitis [26-30], and more
recent evidences are available about the role of obesity on
occurrence of DD complications [31, 32]. Overall consensus
about these statement was very high, since all of them reached
>80% agreement among respondents.

2. Course of the disease

2.1 Symptomatic Uncomplicated Diverticular Disease
(SUDD) is a distinct clinical syndrome characterized by
recurrent abdominal symptoms attributed to diverticula in
the absence of clinical, laboratory, or radiographic markers
of overt inflammation. [EL: 1c; GR: B]
Consensus levels of agreement: A+ 49.19%; A 37.10%; A-
11.29%; D- 0%; D 1.61%; D+ 0.81%.

2.2 The pathophysiology is SUDD is poorly understood,
with some evidence suggesting altered colonic motility, visceral
hypersensitivity, microbiome alterations and/or subclinical
inflammation playing etiological roles. [EL: 4; GR: D]
Consensus levels of agreement: A+ 55.65%; A 30.65%; A-
12.10%; D- 0.81%; D 0.81%; D+ 0%.

2.3 There is no evidence to suggest that bowel habits
or a change in those habits determine the evolution to
diverticulitis. [EL: 1c; GR: B]
Consensus levels of agreement: A+ 48.49%; A 33.06%; A-
12.90%; D- 4.03%; D 0%; D+ 0.81%.

2.4 SUDD post-acute diverticulitis is a chronic
inflammatory disease with prolonged chronic symptoms, high
levels of systemic serum inflammatory markers, high levels
of tissue inflammatory cytokine and chronic inflammatory
infiltrates in the affected colonic tissue. [E: 2c; GR: B]
Consensus levels of agreement: A+ 49.19%; A 18.55%; A-
20.16%; D- 8.87%; D 1.81%; D+ 1.81%.

2.5 There is still no definite evidence that rifaximin reduces
acute episodes of diverticulitis. [EL: 4; GR: D]
Consensus levels of agreement: A+ 45.57%; A 39.52%; A-
8.06%; D- 4.84%; D 1.61%; D+ 0%.

2.6 There are some evidences that mesalazine could reduce
symptoms following acute episode of diverticulitis. [EL: 3a; GR: B]
Consensus levels of agreement: A+ 17.74%; A 49.19%; A-
28.23%; D- 1.61%; D 1.61%; D+ 1.61%.
2.7 At present, there is no evidence that mesalazine reduces acute episodes of diverticulitis. [EL: 1c; RG: B]

Consensus levels of agreement: A+ 52.42%; A 28.23%; A- 11.29%; D- 5.65%; D: 1.61%; D+ 0.81%.

Comments
These statements point out the new evidences about the evolution of diverticulosis towards occurrence of SUDD and acute diverticulitis. The first two statements define clearly that SUDD is a distinct clinical syndrome, with distinct clinical characteristics from irritable bowel syndrome (IBS) [33, 34], and have specific characteristics about cytokine expression and microbiota signature [24, 35-39]. The third statement clarify that, based on current evidences, changing of bowel habits do not seems to influence the evolution towards AD [40]. The forth statement points out patients experiencing SUD following an episode of acute diverticulitis have persistence of inflammation in terms of histological inflammation and increased expression of cytokines, findings that underscores the risk of AD recurrence [41, 42]. The last three statements point out that, at present, there are no clear evidences on how to prevent AD occurrence and its recurrence. Neither rifaximin nor mesalazine seems to be effective on both these topics [5, 43-44], while mesalazine seems to reduce symptoms following an episode of AD [45, 46]. This because the trial design was not optimal, and this was particularly true for trials investigating mesalazine. Also the overall consensus about this statement was very high, since all of them reached >80% agreement among respondents.

3. Diagnosis

3.1 No single biomarker is sensitive and specific enough to be recommended as diagnostic tool for symptomatic uncomplicated diverticular disease. [EL: 1a; GR: A]

Consensus levels of agreement: A+ 83.87%; A 15.32%; A- 0%; D- 0%; D: 0.81%; D+ 0%.

3.2 C-reactive protein levels >150 mg/l strongly predicts complicated diverticulitis. [EL: 1a; GR: A]

Consensus levels of agreement: A+ 43.55%; A 50%; A- 6.45%; D- 0%; D: 0%; D+ 0%.

3.3 Faecal Calprotectin might be useful in distinguishing symptomatic uncomplicated diverticular disease from irritable bowel syndrome, but a cut-off level needs to be identified. [EL: 3c; GR: C]

Consensus levels of agreement: A+ 38.71%; A 45.97%; A- 8.87%; D- 0.81%; D: 2.42%; D+ 3.23%.

3.4 Contrast-enhanced computer tomography (CE-CT) should be considered as the first-line colonic examination since it offers a more comprehensive evaluation of uncomplicated and complicated forms; CE-CT can also be used to guide therapeutic interventions. [EL: 1b; GR: A]

Consensus levels of agreement: A+ 38.71%; A 45.97%; A- 8.87%; D- 0.81%; D: 2.42%; D+ 3.23%.

3.5 Ultrasound has slightly lower sensitivity and specificity compared to CT in the assessment of acute diverticulitis and its use as the first-line diagnostic procedure - followed by CT scan in the case of inconclusive sonographic findings - may spare the use of CT in more than 50% of cases. [EL: 1a; GR: A]

Consensus levels of agreement: A+ 55.65%; A 23.39%; A- 18.55%; D- 1.61%; D: 0.81%; D+ 0%.

3.6 Ultrasound coupled with i.v. contrast agents (CEUS) differentiates between peri-intestinal phlegmon and abscess and demonstrates the real extension of the abscess in acute diverticulitis.

Ultrasound-guided drainage, when feasible, is the preferable option for abscesses larger than 3 cm. [EL: 4; GR: C]

Consensus levels of agreement: A+ 50%; A 41.13%; A- 0%; D- 0.81%; D: 0%; D+ 0%.

3.7 Ultrasound is useful to monitor the patients after the acute diverticulitis and in particular the lesions treated conservatively. [EL: 2b; GR: B]

Consensus levels of agreement: A+ 33.87%; A 48.39%; A- 15.39%; D- 2.42%; D: 0%; D+ 0%.

3.8 Ultrasound may be of help in detecting symptomatic uncomplicated diverticular disease (SUDD) of the colon. [EL: 4; GR: C]

Consensus levels of agreement: A+ 27.42%; A 52.42%; A- 13.71%; D- 3.23%; D: 1.61%; D+ 1.61%.

3.9 A prompt colonoscopy (i.e. within 12-24 h) is mandatory for diagnosis and to direct therapy in diverticular bleeding. Massive bleeding should be managed with selective angiography. [EL: 2a; GR: B]

Consensus levels of agreement: A+ 45.97%; A 41.94%; A- 6.45%; D- 5.65%; D: 0%; D+ 0%.

3.10. DICA endoscopic classification seems to have a predictive value on the outcome of the disease. EL: 1b; GR: B

Consensus levels of agreement: A+ 47.58%; A 45.97%; A- 4.03%; D- 2.42%; D: 0%; D+ 0%.

Comments
These statements point out the new evidences about the role of diagnosis in diagnosing and managing SUDD and AD. The first three statements confirm the important predicting value of C-reactive protein (CRP) in define the presence and the severity of acute diverticulitis [47, 48], and that fecal calprotectin (FC) may be useful in differentiating between SUDD and IBS [35]. The forth statement confirms that the contrast-enhanced computer tomography is the gold standard to pose the diagnosis of AD and its complications [49]. The statements 3.5-3.8 underscore the increasing role of the intestinal ultrasound (IUS) in diagnosis both SUDD and AD, underscoring also the limit of this technique, namely that it operator-sensitive [50-52]. The statement 3.9 points out the role of colonoscopy in those people. In particular, it underscore the role of colonoscopy in managing diverticular bleeding, which is the main cause of lower gastrointestinal bleeding and linked to the advanced age and the numerous, associated comorbidities [53-55]. The last statement point out the attention on the first validated endoscopic classification on diverticulosis and
diverticular disease, called DICA (Diverticular Inflammation and Complication Assessment) [55]. This classification, very easy to use, has a significant predicting value on the outcome of the disease (57), and has also a significant interobserver agreement in real life [58]. The overall consensus about these statement was very high, since all of them reached >80% agreement among respondents.

4. Medical treatment

4.1 Rifaximin plus fibre is effective in reducing symptoms in SUDD patients compared to fibre alone. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 66.94%; A 28.23%; A- 3.23%; D- 1.61%; D: 0%; D+ 0%.

4.2 Mesalazine is effective in reducing symptoms in SUDD patients. [EL: 1b; GR: A]
Consensus levels of agreement: A+ 51.61%; A 34.68%; A- 11.29%; D- 1.61%; D: 0.81%; D+ 0%.

4.3 There are some evidences that probiotics could be effective in reducing symptoms in SUDD patients [EL: 3a; GR: B]
Consensus levels of agreement: A+ 32.26%; A 36.29%; A- 28.23%; D- 3.23%; D: 0%; D+ 0.81%.

Comments
These statements focused their attention just on the treatment of SUDD, which is still under active debate. In particular, focusing their attention on the efficacy of non-absorbable antibiotics (namely rifaximin), anti-inflammatory drugs (namely mesalazine), and probiotics. The first statement confirms that rifaximin, especially when associated with fibre, is effecting in reducing symptoms in SUDD [43, 59]. The second statement claims that mesalazine is also effective in reducing symptoms in those people and in preventing its recurrence during the follow-up [46, 60, 61]. The last statement claims that there are some interesting news in using probiotics in those people [61, 62], but data are still too heterogeneous to drawn any definite conclusions. It is noteworthy the impressive overall consensus about these statement, reaching >90% agreement among respondents.

5. Surgical treatment

5.1 Treatment of acute uncomplicated diverticulitis (AUD) without antibiotics is safe and effective and it is not associated with worse outcomes, including need for surgery, complications, recurrence and length of hospital stay. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 28.23%; A 41.94%; A- 13.71%; D- 8.87%; D: 3.23%; D+ 4.03%.

5.2 In Uncomplicated Acute Diverticulitis antibiotic therapy is still considered in patients immunocompromised, with severe comorbidities (ASA >2) and with sign of sepsis. [EL: 3b; GR: C]
Consensus levels of agreement: A+ 79.03%; A 20.97%; A- 0%; D- 0%; D: 0%; D+ 0%.

5.3 There are some evidence that high CPR level (>170 mg/ml) or a initial CT findings of fluid collection and longer inflamed colon could be useful factors in selecting patients who could benefit of antibiotic treatment, but these preliminary data need to be confirmed by further studies. [EL: 4; GR: C]
Consensus levels of agreement: A+ 69.35%; A 28.23%; A- 2.42%; D- 0%; D: 0%; D+ 0%.

5.4 The open approach to acute diverticulitis in urgent/emergent setting should be preferred for patients with hemodynamic instability, or when an adequate expertise in colorectal laparoscopy is not available. [EL: 4; GR: B]
Consensus levels of agreement: A+ 82.26%; A 14.52%; A- 3.23%; D- 0%; D: 0%; D+ 0%.

5.5 Laparoscopic resection is safe and provides faster recovery in uncomplicated cases: cases it has to be performed by well-trained surgeons. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 77.42%; A 20.97%; A- 1.61%; D- 0%; D: 0%; D+ 0%.

5.6 Laparoscopic peritoneal lavage may be an alternative to manage purulent peritonitis Hinchey III in diverticular disease. [EL: 4; GR: B]
Consensus levels of agreement: A+ 19.35%; A 50%; A- 16.94%; D- 8.87%; D: 4.84%; D+ 0%.

5.7 The decision to perform elective resection after one or more episodes of AD should be undertaken on a “case-by-case” basis. [EL: 2b; GR: B]
Consensus levels of agreement: A+ 71.77%; A 25%; A- 3.23%; D- 0%; D: 0%; D+ 0%.

Comments
These statements focused their attention mainly on the surgical treatment of treatment of AD, since SUDD has not a surgical recommendation. The first statements are dedicated to the current indication on antibiotic of in the setting of AD. The first claims that the management of acute diverticulitis without antibiotics does not increase these worse outcomes [63-68]. Therefore, the second statement confirms that antibiotics have to be used by a “case-by-case” basis [5, 66], and that some parameters (namely levels of PCR and CT findings at entry) may be predictive on the need to use antibiotics in this population (48,66). The last three statement confirms that the open or the laparoscopic approach to AD, as well as an elective resection after multiple episode of AD have to follow a “case-by-case” basis [69, 73]. It is noteworthy the impressive overall consensus about these statements, since disagreement on them among respondents was almost absent.

6. Critical issues

6.1 Ambulatory treatment of uncomplicated acute diverticulitis is safe, effective and applicable to patients who do not present concomitant unstable comorbid conditions; immunosuppression; cognitive, social, or psychiatric impairment; and intolerance to oral intake.

Outpatient management allows important cost saving to the health systems without negative influence on the quality
of life of patients with uncomplicated diverticulitis. [EL: 1a; GR: A]
Consensus levels of agreement: A+60.48%; A 36.29%; A- 3.23%; D- 0%; D: 0%; D+ 0%.

6.2 Segmental Colitis Associated with Diverticulosis (SCAD) is a chronic inflammation occurring in the colon harboring diverticulosis that seems to resemble a chronic inflammatory disease rather than a complicated diverticular disease.

Treatment options include antibiotics (Ciprofloxin and metronidazole), 5-ASA and probiotics for mild cases. In severe disease the use of systemic steroids might be warranted. Anti TNFα treatment may be beneficial in severe disease resistant to other therapeutic options. Treatment duration might vary depending on clinical response and can last weeks-months. [EL: 2b; GR: C].
Consensus levels of agreement: A+48.39%; A 41.13%; A- 8.87%; D- 0%; D: 0%; D+ 0%.

6.3 Diverticular inflammation is not a causative risk factor for colorectal cancer (CRC) but is an important factor that should be taken into account requiring early colonoscopy to exclude cancer. [EL: 2a; GR: B].
Consensus levels of agreement: A+73.39%; A 22.58%; A- 4.03%; D- 0%; D: 0%; D+ 0%.

Comments
These statements focused their attention on three topics under active debate. The first statement claims about the safety of ambulatory treatment of uncomplicated AD, which is safe and effective [73-79]. Moreover, this approach has also a significant impact on cost-saving [79]. The second statement claims that segmental colitis associated with diverticulosis (SCAD), is a chronic disease occurring in a colon harbouring diverticulosis, and that seems to be a chronic inflammatory bowel disease than a complication of DD [80-83]. This disease may be treated with a variety of treatments, from antibiotic and 5-ASA to anti-TNFα antibodies [84, 85]. The last statement confirms that DD is not a causative risk factor for colorectal cancer (CRC) [86, 87]. However, it should be excluded in patients after an episode of complicated acute diverticulitis, especially when the colon has not been studied never before [88]. It is noteworthy the impressive overall consensus about these statements, since any disagreement was recorded among respondents.

CONCLUSIONS
These guidelines represent a consensus of best practice based on the available evidence as showed at the time of the 3rd International Symposium on Diverticular Disease. The statement proposed and voted during this Symposium have been developed starting from the statements voted during the 2nd International Symposium on Diverticular Disease, held in Rome on April 2016 [5], and have been conceived as an improvement of the points in which there were no clear evidence at that time. This is because these guidelines are not described in a classical way (“epidemiology”, “diagnosis”, “treatment”, etc.), as well as no every finding of the disease has been voted or discussed. On the contrary, the sessions (and the statements, as consequence) have been designed just as improvement of that is already clearly known. The strength of these guidelines is that the statements have been designed by several International experts using a Delphi-like process, and have been approved by a large population of physicians, involving all medical categories managing DD, and coming from European, Northern and Southern America, Australian and African countries.

They may not apply to all situations and should be interpreted in the light of specific clinical situations and resource availability. Further controlled clinical studies may be needed to clarify some aspects of these statements, and revision will definitely be needed, as new data will become available. This is particularly true not only for some medical treatments currently under active debate (in example, how to prevent acute diverticulitis recurrence), but also for some surgical aspects (example when to operate DD).

These Guidelines are not rules, but are intended to be an educational tool to provide information that may assist each medical category (general practitioners, gastroenterologists and surgeons) in providing care to patients, not as encouraging, advocating, requiring, or discouraging any particular treatment.

REFERENCES
1. Strate LL, Modi R, Cohen E, Spiegel BM. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol 2012;107:1486-1493. doi: 10.1038/ajg.2012.194
2. Papa A, Papa V. The Economic Burden of Diverticular Disease. J Clin Gastroenterol 2016;50 Suppl 1:S2-S3. doi: 10.1097/MCG.0000000000000598
3. Krues W, Germer CT, Leifeld L; German Society for Gastroenterology, Digestive and Metabolic Diseases and The German Society for General and Visceral Surgery. Diverticular disease: guidelines of the german society for gastroenterology, digestive and metabolic diseases and the german society for general and visceral surgery. Digestion 2014;90:190-207. doi: 10.1159/000367625
4. Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology 2015;149:1944-1949. doi: 10.1053/j.gastro.2015.10.003
5. Tursi A, Picchio M, Elisei W, Di Mario F; Scarpignato C, Brandimarte M. Management of Patients With Diverticulosis and Diverticular Disease:Consensus Statements From the 2nd International Symposium on Diverticular Disease. J Clin Gastroenterol 2016;50 Suppl 1:S101-S107. doi: 10.1097/MCG.0000000000000654
6. Oxford Centre for Evidence-Based Medicine. Available at: http://www. cebm.net/index.aspx?o=5653
7. Reichert MC, Lammert F. The genetic epidemiology of diverticulosis and diverticular disease: Emerging evidence. United Eur Gastroenterol J 2015;3:409-418. doi: 10.1177/2050641615576676
8. Granlund J, Svensson T, Olén O, et al. The genetic influence on diverticular disease--a twin study. Aliment Pharmacol Ther 2012;35:1103–1107. doi: 10.1111/j.1365-2036.2012.05069.x
9. Strate LL, Erichsen R, Baron JA, et al. Heritability and Familial Aggregation of Diverticular Disease: A Population-Based Study of Twins
and Siblings. Gastroenterology 2013;144:736–742.e1. doi: 10.1053/j.gastro.2012.12.030

10. Connelly TM, Berg AS, Hegarty JP, et al. The TNFSF15 Gene Single Nucleotide Polymorphism rs7848647 Is Associated With Surgical Diverticulitis. Ann Surg 2014;259:1132–1137. doi: 10.1097/SLA.0000000000000232

11. Reichert MC, Kupciniskas J, Krawczyk M, et al. A Variant of COL3A1 (rs3134646) Is associated with risk of developing diverticulosis in white men. Dis Colon Rectum 2018;61:604–611. doi: 10.1097/DCR.0000000000001001

12. Sigurdsson S, Alexandersson KE, Sulem P, et al. Sequence variants in ARHGAP15, COLQ and FAM155A associate with diverticular disease and diverticulitis. Nat Commun 2017;8:15789. doi: 10.1038/ncomms15789

13. Maguire IH, Handelman SK, Du X, Chen Y, Pers TH, Spielietes DK. Genome-wide association analyses identify 39 new susceptibility loci for diverticular disease. Nat Genet 2018;50:1359–1365. doi: 10.1038/s41588-018-0203-z

14. Schafmayer C, Harrison JW, Buch S, et al. Genome-wide association analysis of diverticular disease points towards neuromuscular, connective tissue and epithelial pathomechanisms. Gut 2019;68:854–865. doi: 10.1136/gutjnl-2018-317619

15. Bassotti G, Battaglia E, Bellone G, et al. Interstitial cells of Cajal, enteric nerves, and glial cells in colonic diverticulitis. J Clin Pathol 2005;58:973–977. doi: 10.1136/jcp.2005.026112

16. Fornai M, Colucci R, Antonioli L, et al. Alterations in colonic motility and relationship to pain in colonic diverticulosis. Clin Gastroenterol Hepatol 2005;3:248–253. doi: 10.1016/s1542-3565(04)00614-7

17. Bassotti G, Villanacci V, Bernardini N, Dore MP. Diverticular Disease of the Colon: neuromuscular Function Abnormalities. J Clin Gastroenterol 2016;50 (Suppl 1):S6–S8. doi: 10.1097/MCG.0000000000000578

18. Bassotti G, Battaglia E, De Roberto G, Morelli A, Tonini M, Villanacci V. Alterations in colonic motility and relationship to pain in colonic diverticulosis. Clin Gastroenterol Hepatol 2005;3:248–253. doi: 10.1016/s1542-3565(04)00614-7

19. Bassotti G, Villanacci V, Nascimbeni R, et al. The role of colonic mast cells and myenteric plexitis in patients with diverticular disease. Int J Colorectal Dis 2013;28:267–272. doi: 10.1007/s00384-012-1554-z

20. Humes DJ, Simpson J, Smith J, et al. Visceral hypersensitivity in symptomatic diverticulitis disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 2012;24:318–e163. doi: 10.1111/j.1365-2982.2011.01863.x

21. Tursi A. Endoscopic Diagnosis of Diverticulitis and Diagnosis of Symptomatic Uncomplicated Diverticulitis Disease of the Colon: If You Properly Classify, You Properly Make the Diagnosis. Am J Gastroenterol 2015;110:1349–1350. doi: 10.1038/ajg.2015.113

22. Peery AF, Keku TO, Addamo C, et al. Colonic Diverticula Are Not Associated With Mucosal Inflammation or Chronic Gastrointestinal Symptoms. Clin Gastroenterol Hepatol 2016;14:884–891.e1. doi: 10.1016/j.cgh.2015.05.051

23. Jarbrink-Sehgal ME, Rassam I, Jasim A, et al. Diverticulosis, Symptoms and Colonic Inflammation:A Population-Based Colonoscopy Study. Am J Gastroenterol 2019;114:500–510. doi: 10.1039/a0000000000000113

24. Humes DJ, Simpson J, Smith J, et al. Visceral hypersensitivity in symptomatic diverticulitis disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 2012;24:318–e163. doi: 10.1111/j.1365-2982.2011.01863.x

25. Tursi A, Brandimarte G, Elisei W, et al. Assessment and grading of mucosal inflammation in colonic diverticulitis disease. J Clin Gastroenterol 2008;42:699–703. doi: 10.1097/MCG.0b013e3180633ca2

26. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr 1994;60:757–764. doi: 10.1093/ajcn/60.5.757

27. Aldoori WH, Giovannucci EL, Rockett HR, Sampson L, Rimm EB, Willett WC. A prospective study of dietary fiber types and symptomatic diverticular disease in men. J Nutr 1998;128:714–719. doi: 10.1203/jn/128.4.714

28. Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC):prospective study of British vegetarians and non-vegetarians. BMJ 2011;343:d4131. doi: 10.1136/bmj.d4131

29. Crowe FL, Balkwill A, Cairns BJ, et al. Source of dietary fibre and diverticular disease incidence: a prospective study of UK women. Gut 2014;63:1450–1456. doi: 10.1136/gutjnl-2013-304644

30. Strate LL, Keeley BR, Cao Y, Wu K, Giovannucci EL, Chan AT. Western Dietary Pattern Increases, and Prudent Dietary Pattern Decreases, Risk of Incident Diverticulitis in a Prospective Cohort Study. Gastroenterology 2017;152:1023–1030.e2. doi: 10.1053/j.gastro.2016.12.038

31. Hjern F, Wolk A, Hakansson N. Obesity, physical inactivity, and colonic diverticular disease requiring hospitalization in women:a prospective cohort study. Am J Gastroenterol 2012;107:296–302. doi: 10.1038/ajg.2011.352

32. Ma W, Jovani M, Liu PH, et al. Association Between Obesity and Weight Change and Risk of Diverticulitis in Women. Gastroenterology 2018;155:58–66.e4. doi: 10.1053/j.gastro.2018.03.057

33. Cuomo R, Barbana G, Andreozzi P, et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013;43:1147–1155. doi: 10.1111/eci.12152

34. Tursi A, Elisei W, Picchio M, Giorgetti GM, Brandimarte G. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticulitis disease of the colon: a comparison with fecal calprotectin in clinical setting. J Clin Gastroenterol 2015;49:218–221. doi: 10.1097/MCG.0000000000000094

35. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Fecal calprotectin in colonic diverticular disease: a case–control study. J Clin Gastroenterol Dis 2009;20:49:49–55. doi: 10.1007/s00384-008-0595-9

36. Tursi A, Elisei W, Brandimarte G, et al. Mucosal expression of basic fibroblast growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case–control study. Neurogastroenterol Motil 2012;24:318–e163. doi: 10.1111/j.1365-2982.2011.01863.x

37. Tursi A. Mastomarino P, Capobianco D, et al. Assessment of fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticulitis disease of the colon. J Clin Gastroenterol 2016;50 Suppl 1:S9–S12. doi: 10.1097/MCG.0b013e3186366b95

38. Barbana G, Scioli E, Barbaro MR, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticulitis disease. Gut 2017;66:1252–1261. doi: 10.1136/gutjnl-2016-312377

39. Kvasnovsky CL, Leong LEX, Choo JM, et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease: a pilot study. Eur J Gastroenterol Hepatol 2016;30:107–112. doi: 10.1097/MEG.0000000000009995
40. Gao R, Tao Y, Zhou C, et al. Exercise therapy in patients with constipation: a systematic review and meta-analysis of randomized controlled trials. Scand J Gastroenterol 2019;54:169-177. doi:10.1080/03007995.2019.1658544

41. Lahat A, Necula D, Yavvori M, et al. Prolonged Recurrent Abdominal Pain is Associated With On-going Underlying Mucosal Inflammation in Patients who had an Episode of Acute Complicated Diverticulitis. J Clin Gastroenterol 2019;53:e178-185. doi:10.1097/MCG.0000000000000980

42. Tursi A, Elisi W, Giorgetti GM, et al. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. J Gastrointestin Liver Dis 2013;22:13-19.

43. Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticulitis. Aliment Pharmacol Ther 2011;33:902-910. doi:10.1111/j.1365-2036.2011.04606.x

44. Raskin JB, Kamm MA, Jamal MM, et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology 2014;147:793-802. doi:10.1053/j.gastro.2014.07.004

45. Andeweg CS, Knobben L, Hendriks JC, et al. The role of C-reactive protein in prediction of the severity of acute diverticulitis in an emergency unit. Scand J Gastroenterol 2015;50:536-541. doi:10.1007/s10153-014-099350

46. Ambrosetti P. Acute left-sided colonic diverticulitis: clinical expressions, therapeutic insights, and role of computed tomography. Clin Exp Gastroenterol 2016;9:249-257. doi:10.2147/CEG.S110428

47. Lamers W, Van Randen A, Bipat S, Bossuyt PM, Boermeester MA, Stoker J. Graded compression ultrasonography and computed tomography in acute colonic diverticulitis: meta-analysis of test accuracy. Eur Radiol 2008;18:2498-2511. doi:10.1007/s00330-008-1018-6

48. Dirks K, Calabrese E, Dietrich CF, et al. EFSUMB Position Paper: Recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis. Ultraschall Med 2019;40:163-175. doi:10.1055/a-0824-6952

49. Van Randen A, Lamers W, van Es HW, et al. A comparison of the accuracy of ultrasound and computed tomography in common diagnoses causing acute abdominal pain. Eur Radiol 2011;21:1535-1545. doi:10.1007/s00330-011-2087-5

50. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1997;92:419-424.

51. Nagata N, Nakura R, Aoki T, et al. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antplatelet drugs, and dual therapy. J Gastroenterol Hepatol 2014;19:1786-1793. doi:10.1111/jgh.12595

52. van Randen A, Lameris W, Van Randen A, Bipat S, et al. A comparison of the accuracy of ultrasound and computed tomography in common diagnoses causing acute abdominal pain. Eur Radiol 2011;21:1535-1545. doi:10.1007/s00330-011-2087-5

53. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1997;92:419-424.

54. Nagata N, Nakura R, Aoki T, et al. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-dose aspirin, antplatelet drugs, and dual therapy. J Gastroenterol Hepatol 2014;19:1786-1793. doi:10.1111/jgh.12595

55. Wong Kee Song LM, Baron TH. Endoscopic management of acute lower gastrointestinal bleeding. Am J Gastroenterol 2008;103:1881-1887.

56. Tursi A, Brandimarte G, Di Mario F, et al. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. Dig Dis 2015;33:68-76. doi:10.1111/j.1412-8963.2014.01044.x

57. Tursi A, Brandimarte G, Di Mario F, et al; DICA Collaborative Group. Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticulitis disease of the colon: an international study. United European Gastroenterol J 2016;4:604-613. doi:10.11177/2050640615617636

58. Tursi A, Brandimarte G, Di Mario F, et al; DICA Italian Group. The “DICA” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. J Gastrointestin Liver Dis 2019;28:23-27. doi:10.15403/jgld.2014.1121.281.dic

59. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticulosis of the colon. A multicenter double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995;9:33-39. doi:10.1111/j.1365-2036.1995.tb00348.x

60. Emile SH, Elfeki H, Sakr A, Shalaby M. Management of acute uncomplicated diverticulitis without antibiotics: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2013;38:741-751. doi:10.1111/apt.12463

61. The role of antibiotics in acute uncomplicated diverticulitis: A systemic review and meta-analysis. Dis Colon Rectum 2015;58:298-307. doi:10.1007/s10455-014-9749-2

62. Tursi A, Brandimarte G, Elisi W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticulitis disease—a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 2013;38:741-751. doi:10.1111/apt.12463

63. Emile SH, Elfeki H, Sakr A, Shalaby M. Management of acute uncomplicated diverticulitis without antibiotics: a systematic review, meta-analysis, and meta-regression of predictors of treatment failure. Tech Coloproctol 2018;22:499-509. doi:10.1007/s10787-018-1817-y

64. Mocanu V, Dang JT, Switzer N, et al. The role of antibiotics in acute uncomplicated diverticulitis: A systematic review and meta-analysis. Dis Colon Rectum 2014;57:640-650. doi:10.1007/s10047-013-0324-8

65. Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics Versus No Antibiotics for Acute Uncomplicated Diverticulitis: A Systematic Review and Meta-Analysis. Dis Colon Rectum 2019;62:1005-1012. doi:10.1007/s10047-019-03027-w

66. Azhar N, Kusdat H, Palsson B, Kurt Schultz J, Lydrup ML, Buchwald P. Acute uncomplicated diverticulitis managed without antibiotics - difficult to introduce a new treatment protocol but few complications. Scand J Gastroenterol 2019;54:64-68. doi:10.1002/1096-0890.2018.1552987

67. Tandon A, Fretwell VL, Nunes QM, Rooney PS. Antibiotics versus no antibiotics in the treatment of acute uncomplicated diverticulitis - a systematic review and meta-analysis. Colorectal Dis 2018;20:1013-1019. doi:10.1111/codi.14013

68. Au S, Aly EH. Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-Analysis. Dis Colon Rectum 2019;62:1533-1547. doi:10.1007/s10047-019-03130-0

69. Di Saverio S. Emergency laparoscopy: a new emerging discipline for treating abdominal emergencies attempting to minimize costs and
invasiveness and maximize outcomes and patients’ comfort. J Trauma Acute Care Surg 2014;77:338-350. doi:10.1097/TA.0000000000000288

70. Klarenbeek BR, Veenhof AA, Bergamaschi R, et al. Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: a randomized control trial short-term results of the Sigma Trial. Ann Surg 2009;249:39-44. doi:10.1097/SLA.0b013e31818e416a

71. Gervaz P, Inan I, Perneger T, Schiffer E, Morel P. A prospective, randomized, single-blind comparison of laparoscopic versus open sigmoid colectomy for diverticulitis. Ann Surg 2010;252:3-8. doi:10.1097/SLA.0b013e3181dbb5a5

72. Cirocchi R, Farinella E, Trastulli S, Sciannnameo F, Audisio RA. Elective sigmoid colectomy for diverticular disease. Laparoscopic vs open surgery: a systematic review. Colorectal Dis 2012;14:671-683. doi:10.1111/j.1463-1318.2011.02666.x

73. Kohl A, Rosenberg J, Bock D, et al. Two-year results of the randomized clinical trial DILALA comparing laparoscopic lavage with resection as treatment for perforated diverticulitis. Br J Surg 2018;105:1128-1134. doi:10.1002/bjs.10839

74. Isacson D, Thorisson A, Andreasson K, Nikberg M, Smedh K, Chabok A. Outpatient, non-antibiotic management in acute uncomplicated diverticulitis: risk factors for treatment failure. Int J Colorectal Dis 2015;30:1229-1234. doi:10.1007/s00384-015-2258-y

75. Biondo S, Golda T, Kreisler E, et al. Outpatient versus hospitalization management for uncomplicated diverticulitis: a prospective, multicenter randomized clinical trial (DIVERTrial). Ann Surg 2014;259:38-44. doi:10.1097/SLA.0b013e31829665a11

76. Sánchez-Velázquez P, Grande L, Pera M. Outpatient treatment of uncomplicated diverticulitis: a systematic review. Eur J Gastroenterol Hepatol 2016;28:622-627. doi:10.1097/MEG.0000000000000610

77. Bolkenstein HE, Draaisma WA, van de Wall B, Consten E, Broeders I. Treatment of acute uncomplicated diverticulitis without antibiotics: risk factors for treatment failure. Int J Colorectal Dis 2018;33:863-869. doi:10.1007/s00384-018-3055-1

78. Rottier SJ, van Dijk ST, Ünlü Ç, van Geloven AAW, Schreurs WH, Boermeester MA. Complicated Disease Course in Initially Computed Tomography-Proven Uncomplicated Acute Diverticulitis. Surg Infect (Larchmt) 2019;20:453-459. doi:10.1089/sur.2018.289

79. Mills AM, Holena DN, Kallan MJ, Carr BG, Reineke CE, Kelz RR. Effect of insurance status on patients admitted for acute diverticulitis. Colorectal Dis 2013;15:613-620. doi:10.1111/codi.12066

80. Tursi A. Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity? Dig Dis Sci 2011;56:27-34. doi:10.1007/s10620-010-1230-5

81. Imperiali G, Meucci G, Alvisi C, et al. Segmental colitis associated with diverticula: a prospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000;95:1014-1016.

82. Mann NS, Hoda KK. Segmental colitis associated with diverticulosis: systematic evaluation of 486 cases with meta-analysis. Hepatogastroenterology 2012;59:2119-2112.

83. Ludeman L, Shepherd NA. What is diverticular colitis? Pathology 2002;34:568-572. doi:10.1080/0031302020000035974

84. Schembri J, Bonello J, Christodoulou DK, Katsanos KH, Ellul P. Segmental colitis associated with diverticulosis: is it the coexistence of colonic diverticularis and inflammatory bowel disease? Ann Gastroenterol 2017;30:257-261. doi:10.20524/aog.2017.0126

85. Tursi A, Elisei W, Giorgetti GM, et al. Segmental colitis associated with diverticulosis: a 5-year follow-up. Int J Colorectal Dis 2012;27:179-185. doi:10.1007/s00384-011-1296-3

86. Huang WY, Lin CC, Jen YM, et al. Association between colonic diverticular disease and colorectal cancer: a nationwide population-based study. Clin Gastroenterol Hepatol 2013;12:1288-1294. doi:10.1016/j.cgh.2013.11.039

87. Mortensen LQ, Burcharth J, Andersen K, Pommeggaard HC, Rosenberg J. An 18-Year nationwide cohort study on the association between diverticulitis and colon cancer. Ann Surg 2017;265:954-959. doi:10.1097/SLA.0000000000001794

88. Meyer J, Orca IA, Combs J, et al. Risk of Colorectal Cancer in Patients With Acute Diverticulitis: A Systematic Review and Meta-analysis of Observational Studies. Clin Gastroenterol Hepatol 2019;17:1448-1456.e17. doi:10.1016/j.cgh.2018.07.031